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Atrial ﬁbrillation (AF) is associated with an increased risk of cardiac and overall mortality. Restoration and maintenance of sinus
rhythm is of paramount importance if it can be accomplished without the use of antiarrhythmic drugs. Catheter ablation has
evolved into a well-established treatment option for patients with symptomatic, drug-refractory AF. Ablation strategies which
target the pulmonary veins are the cornerstone of AF ablation procedures, irrespective of the AF type. Ablation strategies in
the setting of persistent and long-standing persistent AF are more complex. Many centers follow a stepwise ablation approach
including pulmonary vein antral isolation as the initial step, electrogram-based ablation at sites exhibiting complex fractionated
atrial electrograms, and linear lesions. Up to now, no single strategy is uniformly eﬀective in patients with persistent and long-
standing persistent AF. The present study reviewed the eﬃcacy of the current ablation strategies for persistent and long-standing
persistent AF.
1.Introduction
Atrial ﬁbrillation (AF) is associated with a 2-fold risk of
cardiac and overall mortality [1]. Restoration and main-
tenance of sinus rhythm is of paramount importance if
it can be accomplished without the use of antiarrhythmic
drugs [2]. Catheter ablation of AF has been widely accepted
as an important therapeutic modality for the treatment of
patients with symptomatic AF, refractory or intolerant to
at least one class I or III antiarrhythmic medication [3–5].
Previous studies have clearly demonstrated the superiority
of catheter ablation over antiarrhythmic drug treatment,
even in patients with persistent AF [6–11]. The recently
published ESC guidelines state that ablation of persistent
symptomatic AF that is refractory to antiarrhythmic therapy
should be considered a treatment option (class IIa, level of
evidenceB)[5].In addition, catheterablation of AF may also
be considered in patients with symptomatic long-standing
persistent AF refractory to antiarrhythmic drugs (class IIb,
l e v e lo fe v i d e n c eC )[ 5].
Following the work of Ha¨ ıssaguerre et al. [12], catheter
ablation of paroxysmal AF aiming at electrical pulmonary
vein isolation (PVI) results in maintenance of sinus rhythm
in60to85%ofpatients[13,14].Onthecontrary,PVIiscon-
sidered insuﬃcient to eliminate persistent or long-standing
persistent AF (more that one year) leading to signiﬁcantly
lower success rate of this method [3, 4, 15, 16]. Substrate
modiﬁcation is usually required in the setting of persistent
and long-standing persistent AF [15, 16]. Although diﬀerent
ablation strategies have been reported in persistent and
long-standing persistent AF, the reproducibility of these
techniques is considered inconsistent. This paper highlights
on the current catheter ablation strategies for persistent and
long-standing persistent AF.
2.Pathophysiology ofAtrialFibrillation
The pathophysiology of AF is multifactorial, complex, and
not well deﬁned. Up to date, two main theories have been
reported for the initiation and maintenance of AF. The2 Cardiology Research and Practice
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Figure 1: Three-dimensional reconstruction of the left atrium
using the CARTO 3 map system (Biosence Webster, USA) showing
large circumferential ablation lesions around both ipsilateral veins.
In this example, additional radiofrequency energy was applied on
the interpulmonary isthmus following the large circumferential
lesion creating a “ﬁgure of eight” model. LSPV: left superior
pulmonary vein; LIPV: left inferior pulmonary vein; RSPV: right
superior pulmonary vein; RIPV: right inferior pulmonary vein.
single-focus hypothesis advocates that AF is due to a single
automatic focus or a microreentrant circuit [5, 17]. Triggers
that originate from the PVs and other thoracic veins appear
to be the primary mechanism of AF, particularly in subjects
with paroxysmal AF [5, 12, 18]. The multiple re-entrant
wavelet hypothesis supports that fractionation of wavefronts
propagating through the atria results in self-perpetuating
“daughter wavelets” [19,20].Multiplere-entrantwaveletsare
separated by lines of functional conduction block, and AF
is perpetuated by slowed conduction, increased atrial mass,
and shorter refractory periods [5, 19, 20]. The relationship
betweenthesemechanismsiscomplex,andtheyoftencoexist
in the same patient, particularly in the setting of persistent
AF or long-standing persistent AF [21]. Autonomic factors
have also been implicated in the generation of complex
fractionated atrial electrograms (CFAEs), an important
substrate of AF [3, 4]. Electroanatomic remodeling that
develops as AF progresses from paroxysmal to persistent
and permanent has been well demonstrated to further
facilitate AF (“AF begets AF”) [22]. Atrial dilation, interstitial
ﬁbrosis, uncoupling of the myoﬁbrils, loss of myoﬁbrils,
deposition of extracellular matrix, loss of gap junctions,
resultant anisotropy, conduction slowing and/or block, and
shortening of the eﬀective refractory period may facilitate re-
e n t r y ,w h i c hi sc r i t i c a lt op e r p e t u a t i o no fA F[ 3]. As a result
of progressive electroanatomic remodelling, mechanisms
other than PV arrhythmogenicity are strongly involved and
perpetuate AF. Therefore, in addition to PVI, left atrial
ablation that modiﬁes the substrate is required in the setting
of persistent and long-standing persistent AF.
3. Ablation Strategies and
Success RatesinPersistentAF
3.1. Pulmonary Vein Antral Isolation. Ablation strategies
which target the PV ostium or the PV antrum aiming at
electrical disconnection of the PVs are the cornerstone
of AF ablation procedures. Initial attempts targeted the
arrhythmogenic activity within the PVs using a focal
approach [12]. Due to the high risk of PV stenosis and
the high rate of recurrence, complete electrical isolation
of the PVs by segmental ostial ablation quickly replaced
the initial approach [23, 24]. Successful electrical isolation
is deﬁned by loss of PV potentials (entrance block) and
failure to capture left atrium during pacing from the PV
(exit block) (Figure 1). Pappone et al. have introduced the
circumferential PV ablation (PV antral ablation) without
electrical PV disconnection [25]. This technique involves
applications of radiofrequency energy 1-2cm away from
the ostia of the PVs until the local electrogram amplitude
decreased by ≥80% or to <0.1mV. In a randomized trial,
Arentz et al. have demonstrated that isolation of a large
circumferential area around both ipsilateral PVs with veriﬁ-
cation of conduction block (pulmonary vein antral isolation
(PVAI)) is a more eﬀective treatment of AF than isolation
of each individual PV using a segmental approach [26].
The end point of ablation is the absence or dissociation of
residual PV potentials in the isolated area as documented
with the circular mapping catheter. Figure 2 shows the three-
dimensional reconstruction of the left atrium with large
circumferential ablation lesions around both ipsilateral veins
and additional ablation lines on the interpulmonary isthmus
creating a “ﬁgure of eight” model.
Segmental PVI or PVAI conﬁrmed by absence or dis-
sociation of PV potentials is the most eﬀective strategy
for treatment of most patients with paroxysmal AF [27–
29]. Despite achieving a very high rate of electrical PVI,
PVI strategies alone have consistently demonstrated a lower
success rate in patients with persistent and long-standing
persistent AF compared to paroxysmal AF [3, 4, 29–32].
PVI alone in persistent and long-standing persistent AF was
associated with a single-procedure, drug-free success rate
ranging from 21% to 22% at almost 2 years [33]. On the
contrary, PVAI display higher success rates. In a randomized
trial, Oral et al. have shown that the success rate of the index
procedure after successful PVAI was 36% in patients with
long-standing persistent AF [34]. In the same line, Elayi et al.
reported a 40% success rate following PVAI in patients with
long-standing persistent AF [35]. In a recent study, Tilz et
al. have shown that PVAI is suﬃcient to restore SR in 43.2%
of patients with long-standing persistent AF [36]. Cheema
et al. have demonstrated that single-procedure success rate is
higherinpatientswhowereinAFfor ≤1yearcomparedwith
those in AF for >1 year (50% versus 20%, resp.) [37]. The
variations in success rates of these studies may be attributed
to the diﬀerent deﬁnitions of long-standing AF as well as at
the diﬀerent end-points for AF ablation. Nevertheless, PVAI
withelectricaldisconnectionoftheencircledveinswithinthe
ablated margins has become the preferable ablation strategy
in patients with persistent and long-standing persistent
AF. It is of major importance to perform a continuous
circumferential line around both ispilateral PVs, and then
to validate for electrical PV disconnection aiming at the
earliest residual potential recorded by the circular mapping
catheter.Cardiology Research and Practice 3
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Figure 2: Pulmonary vein (PV) potentials recorded from the Lasso catheter bipoles during pacing from the coronary sinus (CS 3/4). In this
example, the PV potentials are disappeared in the third-paced beat indicating entrance block.
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Figure 3: Three-dimensional reconstruction of the left atrium
using the CARTO 3 map system (Biosence Webster, USA) showing
large circumferential ablation lesions around both ipsilateral veins
along with roof and anterior lines. LAA: left atrial appendage;
LSPV: left superior pulmonary vein; LIPV: left inferior pulmonary
vein; RSPV: right superior pulmonary vein; RIPV: right inferior
pulmonary vein.
3.2. Linear Ablation. Based on the high success rates of
surgical MAZE procedures [38], several attempts have been
made to reproduce these results by percutaneous catheter-
based linear ablations. Linear lesions are intended to mod-
ify the arrhythmogenic LA substrate and atrial macro-re-
entrant circuits involved in maintenance of AF [30, 31, 39,
40]. Addition of linear lesions has been associated with
conversion of AF either directly to sinus rhythm or to
atrial tachycardia (AT), demonstrating that such lesions
signiﬁcantly modify the substrate for AF [40]. Linear lesions
usually include a roof line connecting the left and right
superior PVs and a mitral line connecting the mitral annulus
to the left inferior PV (Figure 3)[ 30, 31, 39, 40]. An anterior
line connecting the anterior or anterolateral mitral annulus
with the left superior PV has been also proven eﬀective for
the treatment of perimitral ﬂutter (Figure 3)[ 41]. Knecht
et al. showed that although PVI and electrogram-based
ablation without linear lesions are eﬀective for terminating
persistent AF in a signiﬁcant number of patients, macro re-
entrant AT requiring LA linear ablation is very likely to occur
during the overall follow-up period. In this study, after a
followup of more than 2 years, among all the patients ablated
forpersistentAF,96%ultimatelyrequiredarooﬂineand86%
amitralline[40].Linearlesionsappliedatthemitralisthmus
or the roof of the LA increase the AF cycle length by a mean
of 20ms and exert a favourable impact on elimination of
AF [39]. In the study of Ja¨ ıs et al., 68% of patients required
an ablation within the coronary sinus facing the endocardial
aspect of the mitral isthmus because of persisting epicardial
conduction [39].
LA linear ablation still remains technically challenging.
Bidirectional block across the lines has to be conﬁrmed
in order to assess completeness of linear lesions [39, 40].
Conduction block of the roof line can be accomplished
more frequently compared with the mitral isthmus line.
When complete linear block could not be achieved during
the index procedure, the incidence of subsequent roof or
mitral isthmus-dependent macro-re-entrant AT is higher. In4 Cardiology Research and Practice
particular, the incidence of macro-re-entrant ATs in patients
with and without conduction block of the roof line at the
index procedure was 19% and 50%, respectively [40]. The
rates for mitral isthmus line were 26% and 56%, respectively
[40].
Willems et al. have investigated the eﬀectiveness of
additional substrate modiﬁcation by left atrial linear lesions
as compared with PVI alone in patients with persistent AF in
a prospective randomized study [42]. After a mean follow-
up time of 487 days, only 20% of patients undergoing stand
alone PVI remained in sinus rhythm when compared with
69% following PVI combined with substrate modiﬁcation.
This study clearly shows that PVI alone is insuﬃcient for
the treatment of patients with persistent AF. In the same
line, Fassini et al. conﬁrmed the additional beneﬁt of mitral
isthmus ablation in patients with persistent AF [43]. In a
systematic review, PV antral ablation or PVAI along with
linear substrate modiﬁcation was associated with a single-
procedure, drug-free clinical success rate ranging from 11%
to 74% at approximately 1.5 years [33]. The highly variable
success rate is possibly related to diﬀerent procedural end-
points and/or criteria for linear lesion contiguity.
3.3. Complex-Fractionated Atrial Electrograms. CFAEs areas
represent potential AF substrate sites and are now consid-
ered as important targets for AF catheter ablation [3, 4].
CFAEs indicate sites of slow conduction, wavefront collision,
conduction block, or anchor points for reentrant circuits
based on the ﬁndings of an epicardial unipolar mapping
study in humans [44]. CFAEs have also been proposed
to indicate sites of ganglionated plexi, as shorter eﬀective
refractory period at these sites would allow higher-frequency
activation [45]. CFAEs were initially deﬁned by Nademanee
et al. as (i) atrial electrograms that are fractionated and
composed of two or more deﬂections averaged over a 10-
second recording period and (ii) atrial electrograms with a
very short cycle length (≤120ms) with or without multiple
potentials when compared with the atrial cycle length
recorded from other parts of the atria [46]. Ha¨ ıssaguerre
et al. performed LA ablation at all sites displaying any
of the following electrogram features: continuous electrical
activity, CFAEs as previously deﬁned, sites with a gradient of
activation (signiﬁcant electrogram oﬀset between the distal
and proximal recording bipoles on the map electrode), or
regions with a cycle length shorter than the mean left atrial
appendage AF cycle length [15]. End points for ablation at
sites of CFAEs include complete elimination of CFAEs or
slowing and organization of local electrograms [15, 46, 47].
An important limitation of this new approach is that CFAEs
are identiﬁed by visual inspection, and therefore this process
is highly dependent on the operator’s judgment. The lack of
a consistent, reproducible technique for measuring CFAEs
represents a signiﬁcant challenge in the implementation of
the results of studies assessing the impact of CFAEs ablation
on procedural outcome. Verma et al. used an automated
algorithm (Ensite NavX, St Jude Medical) to deﬁne CFAEs
sites with cycle lengths ≤120ms [48].
Nademanee et al. have initially showed that ablation of
CFAEs alone resulted in termination of AF without external
cardioversion in 95% of patients persistent or paroxysmal
AF and at one-year followup, 91% of patients were free of
arrhythmia and symptoms [46]. On the contrary, Oral et
al. reported a modest short-term eﬃcacy of the ablation
procedure when targeting only the CFAEs [44]. In particular,
only 33% of patients were in sinus rhythm without the use of
antiarrhythmic drugs after the index ablation [47]. Similarly,
Estner et al. showed that ablation of CFAEs as a stand-
alone ablation strategy seems insuﬃcient for the treatment
of patients with persistent AF [49]. CFAEs ablation alone has
been associated with a single-procedure, drug-free success
rates ranging from 24% to 63% at approximately 1 year [33].
A combined approach of PVI or PVAI and CFAEs
ablation in persistent AF leads to acute AF termination in
66% and long-term maintenance of sinus rhythm in 74%
of cases [50]. The role of ablation of CFAEs following PVAI
wasinvestigatedintworecentrandomizedstudies.Elayietal.
have shown that CFAE plus PVAI (61%) outperformed PVAI
(40%), which was superior to PV antral ablation without
electrical isolation (11%) [35]. Oral et al. randomized 119
consecutive patients with long-standing persistent AF to
PVAI or PVAI and further CFAEs ablation. These authors
found that up to 2h of additional ablation of CFAEs
after PVAI does not appear to improve clinical outcomes
in patients with long-standing persistent AF [34]. In the
same line, Bencsik et al. have recently demonstrated that
CFAEs ablation guided by a dedicated software algorithm
and performed after PVAI had no signiﬁcant impact on the
ﬁbrillatory process and displayed a minor role in achieving
higher rates of termination and noninducibility in patients
with persistent AF [51]. In a systematic review, the single-
procedure, drug-free success rates of CFAEs ablation in
persistent and long-standing persistent AF as an adjunct
to PV antrum ablation, PVAI or PVAI and linear ablation
were 50-51%, 36–61%, and 68%, respectively [33]. A recent
meta-analysis of six randomized trial has demonstrated that
PVI followed by adjunctive CFAEs ablation is associated
with increased freedom from AF after a single procedure
[52]. However, CFAEs ablation signiﬁcantly increased mean
procedural, mean ﬂuoroscopy, and mean radiofrequency
energy application times [52].
3.4. Nonpulmonary Vein Foci. Although the PVs are a
dominant source of AF, non-PV ectopic activity can trigger
AF, and ablation of these ectopic activities can eliminate AF
in a speciﬁc group of patients. Non-PV triggers are more
commonly observed in patients with persistent (8.2%) and
long-standing persistent AF (19.1%) in relation to those
with paroxysmal AF (2.9%) [53]. Ablation of non-PV foci
followingPVIcanorganizepersistentAFintofocalormacro-
re-entrant atrial tachycardias, which can be eliminated,
resulting in maintenance of sinus rhythm in the majority of
patients[54,55].Themajorityofnon-PVfociresponsiblefor
initiation of AF are located in the superior vena cava, crista
terminalis, coronary sinus, LA free wall, LA appendage, and
ligament of Marshall [54, 55].
3.5. Stepwise Catheter Ablation Approach. According to the
Bordeaux group, [15, 16, 30–32, 56, 57] the stepwise catheterCardiology Research and Practice 5
ablation approach for persistent AF includes (i) PVI as the
initial step aiming at elimination of PV electrograms, (ii)
electrogram-based ablation aiming at CFAEs and electro-
grams with activation gradient of at least 70ms between
the distal and proximal recording bipoles of the mapping
catheter, (iii) if AF sustains following PVI and electrogram-
based ablation, linear ablation is carried out including roof
and mitral isthmus lines, (iv) ﬁnally, the right atrium (RA)
and superior vena cava are targeted for ablation if implicated
as a source perpetuating AF and only after all LA ablation
steps. Using this sequential ablation, the Bordeaux group
reported termination of chronic AF (including patients with
persistent AF) by conversion to either sinus rhythm or atrial
tachycardia in 87% of patients during the index procedure
and freedom from AF after an 11-month follow-up period
in 95% of patients [15, 16]. Interestingly, AF was terminated
in only 5% of patients by PVI, in 60% after electrogram-
basedablation,andin84%followinglinearablation[15].AF
cycle length has been reported as the strongest independent
predictor of procedural AF termination [57]. In a similar
study, the single-procedure, drug-free success rate was 55%
[58]. Rostock et al. are the only group outside of Bordeaux to
report on the stepwise procedure in patients with persistent
and long-standing persistent AF. In this series, the stepwise
approach was associated with a lower single-procedure,
drug-free success rate of 38% at 20 months, which improved
to 81% with the integration of repeat procedures [59]. New
studies from diﬀerent centers are required to validate the
eﬃcacy of this ablation strategy.
4. End-Pointsof Catheter Ablation for
PersistentandLong-Standing AF
The goal of catheter ablation in persistent AF is trigger elim-
ination and substrate modiﬁcation. Previous studies have
suggested that termination of AF during ablation in patients
with persistent and long-standing AF is predictive of long-
term maintenance of sinus rhythm [15, 16, 34, 56, 57, 60].
Therefore, restoration of sinus rhythm that occurs directly
or more commonly via one or more intermediate ATs may
be considered as a procedural end-point. It is of paramount
importance to evaluate the presence of electrical PVI as
well as the integrity of linear lesions following restoration
of sinus rhythm. Even though, CFAEs ablation has become
“widespread” in patients with persistent and long-standing
AF, important questions regarding procedural end-points
stillexist.Theprimaryend-pointsduringablationofAFwith
this approach are either complete elimination of the areas
with CFAEs or conversion of AF to sinus rhythm (either
d i r e c t l yo rﬁ r s tt oa nA T )[ 15, 46, 47, 56, 58]. Although
the most robust end-point is AF termination, this generally
requires very long procedure times.
As previously stated, restoration of sinus rhythm appears
an intuitively ideal end-point. In a prospective study of 153
patients who underwent catheter ablation of persistent AF,
a lower incidence of AF recurrence was demonstrated in
those patients in whom AF was terminated during the index
procedure compared to those without termination (5 versus
39%) [56]. During ablation of persistent and long-standing
AF with various strategies, the arrhythmia often organizes
into a regular AT and sometimes even terminates into sinus
rhythm [15]. In a recent prospective study, Elayi et al.
assessed the AF termination mode during catheter ablation
in 306 patients with long-lasting persistent AF and whether
itpredictslong-termsinusrhythmmaintenance[60].During
AF ablation, only 6 out of 306 patients converted directly
to sinus rhythm and 172 patients organized into AT. AF
termination during ablation (conversion to sinus rhythm
or AT) predicts the mode of arrhythmia recurrence (AT
versus AF), but did not impact on long-term sinus rhythm
maintenance after a single or two procedures [60].
In clinical practice, the ideal end-point for AF catheter
ablation is freedom from AF without the use of antiarrhyth-
mic medications. There is much controversy regarding the
monitoring period as well as the minimum acceptable AF
burden. Current deﬁnitions of freedom from AF include
absence of AF, AF episodes lasting up to 30s, and absence
of symptomatic AF [3, 4]. A “blanking period” of up to 3
months after ablation, during which antiarrhythmic medica-
tions may be continued and direct current cardioversion can
be performed for early recurrences of arrhythmias, appears
to be adequate in order to access the eﬃcacy of an ablation
strategy [3, 4].
5. Which Is the Price for an Extensive Ablation
Procedureinthe Settingof PersistentAF?
Longer procedure time, longer ﬂuoroscopy time, higher
complication rates, and high rates of postprocedural ATs are
the main consequences of an extensive ablation procedure
carried out in the setting of persistent and long-standing
persistent AF. In a systematic review of 22 studies (1690
patients with persistent and long-lasting persistent AF),
complicationshavebeenreportedin4.4%andincludedperi-
cardial tamponade/eﬀusion (1.4%), vascular complications
(0.80%), symptomatic pulmonary vein stenosis (0.71%),
cerebrovascular events (0.65%), phrenic nerve injuries
(0.3%), and atrioesophageal ﬁstula (0.06%) [33]. Weber et
al. have also reported the development of pulmonary edema
following AF ablation, possibly in the setting of a systemic
inﬂammatory response syndrome [61]. Cardiac tamponade
is by far the most common fatal complication of AF ablation,
occurring in 0.8–6% [3, 4, 62–67]. Death is an uncommon
complication of AF ablation, occurring in 0.1–0.15% of
subjects [3, 4, 62–67]. Operator’s experience is extremely
important regarding safety issues of catheter ablation of AF.
Spragg et al. reported that complication rates were higher
during the ﬁrst 100 cases (9.0%) than during the subsequent
541 (4.3%) [67]. Table 1 summarizes the most common
complications occurring during catheter ablation of AF.
ATs following the index procedure can occur intraproce-
durally or postprocedurally (early or delayed) [68]. Using a
stepwise ablation strategy, Haissaguerre et al. demonstrated
that persistent AF is usually terminated to an AT (86.5%)
(focal or macro-re-entry) and less frequently directly to
sinus rhythm (13.5%) [15]. This conversion is preceded by6 Cardiology Research and Practice
Table 1: Complications during catheter ablation of persistent and long-standing persistent AF.
Type of complication Symptoms Incidence
Atrio-oesophageal ﬁstula Fever, dysphagia Rare (0.06%)
Vascular complications (Arteriovenous ﬁstula, arterial aneurysm,
haematoma) Pain at puncture site 0.8%
Phrenic nerve injury Cough, dyspnea, atelectasis, and/or thoracic pain 0.3%
Pulmonary vein stenosis Cough, hemoptysis, dyspnea, chest pain, and
recurrent lung infections 0.71%
Pulmonary edema (18–48h after the procedure) Dyspnea, fever, elevated CRP levels Rare
Cerebrovascular events Neurological deﬁcit 0.65%
Tambonade/Eﬀusion Hypotension, dyspnea cardiac arrest 1.4%
(0.8–6%)
Death 0.1–0.15%
prolongation of ﬁbrillatory cycle length, with the greatest
magnitude occurring during ablation at the anterior LA,
coronary sinus, and PV-LA junction [15]. These intrapro-
cedural ATs are more commonly macro-re-entrant circuits
involving the mitral or cavotricuspid isthmus or LA roof
[68, 69]. Postprocedural (secondary) ATs are often incessant
and very poorly tolerated by the patient. Postprocedural ATs
are a rapidly growing clinical problem due to the expansion
of the ablation strategies in the setting of persistent AF
[3, 4]. The incidence of these arrhythmias is higher following
circumferential PV ablation than after segmental PVI and
is even higher when linear ablation is performed within
the LA [68, 69]. ATs have been shown to occur in about
40% of patients who undergo the stepwise ablation approach
[15, 69, 70]. These ATs can be focal or macro-re-entrant.
More recently, a third intermediate AT category called
“localized re-entry” has been reported [69, 70]. Focal ATs
are deﬁned by centrifugal activation from a localized region.
If there is cycle length variation in left atrial appendage
and coronary sinus >15%, focal mechanism is the most
likely diagnosis. However, variation <15% does not rule out
focal mechanism [70]. A macro-re-entrant mechanism is
deﬁned by demonstrating the entire cycle length of activity
in a chamber with entrainment at ≥2 sites displaying a
post-pacing interval of <20msec longer than the tachycardia
cyclelength[70].Mostmacro-re-entrantpostproceduralATs
arise from a proarrhythmic eﬀect of incomplete conduction
block of linear lesions [68–70]. However, Knecht et al.
showed that these macro-re-entrant circuits may also occur
in the majority of patients without previously performed
linear lesions in the long-term followup [40]. PV recovery
should be also considered as a cause of AF recurrence,
but may also contribute to either re-entrant or focal ATs
[68–70]. Management of secondary ATs includes eﬀective
anticoagulation minimizing the risk of thromboembolic
events, prevention of tachycardia-induced cardiomyopathy,
and control of symptoms. One-third of patients whodevelop
ATs in the ﬁrst few weeks after AF ablation may not develop
recurrent atrial arrhythmias during followup [69]. An initial
conservative management strategy including rate control
and cardioversion seems reasonable [68, 69]. Symptomatic
patients with ATs that persist beyond 2-3 months should be
oﬀered catheter ablation [69].
6. Conclusions
In conclusion, catheter ablation of persistent and long-
standing persistent AF remains challenging for the electro-
physiologists. Up to now, no single strategy is uniformly
eﬀective in patients with persistent and long-standing AF.
The risk/beneﬁt ratio of an extensive ablation approach has
to be carefully evaluated. More lesions prolong not only
procedure and ﬂuoroscopy times, but also increase the risk
of complications including ATs. For this purpose, the long-
term success rates of certain ablation strategies need to be
evaluated in randomized trials.
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